Search
Ripretinib
go.drugbank.com/drugs/DB14840ApprovedInvestigational[L13769] It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.[L13778] … Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]
Categories: Stem Cell Factor (KIT) Receptor Inhibitors, Platelet-derived Growth Factor alpha Receptor InhibitorsHydroxyethyl Starch
go.drugbank.com/drugs/DB09106ApprovedInvestigationalHES is a general term and can be sub-classified according to average molecular weight, molar substitution, concentration, C2/C6 ratio and Maximum Daily Dose. … Hydroxyethyl starch (HES/HAES) is a nonionic starch derivative. Hydroxyethyl starches (HES) are synthetic colloids commonly used for fluid resuscitation to replace intravascular volume.
Mixtures: VOLUVEN 6%, VOLUVEN 6%Categories: Compounds used in a research, industrial, or household settingYohimbine
go.drugbank.com/drugs/DB01392ApprovedInvestigationalVet approvedWithdrawnA plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac.
Categories: Adrenergic alpha-2 Receptor Antagonists, Serotonin 5-HT1 Receptor AntagonistsInternational brands: Baron-XRimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigational[L41640] While several parenteral antagonists of CGRP and its receptor have been approved for migraine therapy (e.g. … Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals.
Categories: Calcitonin Gene-Related Peptide Receptor Antagonists, Calcitonin Gene-Related Peptide (CGRP) AntagonistsLunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigationalLunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss. … [L56135,L56136] This landmark decision followed designations as a Regenerative Medicine Advanced Therapy (RMAT) and Fast Track, marking the first-ever gene therapy approved to restore a neurosensory function
Relatlimab
go.drugbank.com/drugs/DB14851ApprovedInvestigationalRelatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3). … [L41305] As immune checkpoint inhibitors have limited efficacy when used alone, drugs like relatlimab have been trialed in combination with other checkpoint inhibitors - for example, PD-1 inhibitors like
Mixtures: OPDUALAG® SOLUCION INYECTABLECategories: Lymphocyte Activation Gene-3 BlockerArbutamine
go.drugbank.com/drugs/DB01102ApprovedArbutamine, administered through a closed-loop, computer-controlled drug-delivery system, is indicated to elicit acute cardiovascular responses, similar to those produced by exercise, in order to aid in
Categories: Adrenergic beta-1 Receptor Agonists, Adrenergic beta-2 Receptor AgonistsPhenytoin
go.drugbank.com/drugs/DB00252ApprovedInvestigationalVet approvedPhenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants. … [A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications
Mixtures: Dilantin W Phenobarbital 15mg, Dilantin W Phenobarbital 30mg CapCategories: Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexEteplirsen
go.drugbank.com/drugs/DB06014ApprovedInvestigationalEteplirsen was first approved by the FDA in September 2016 for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene, which codes for dystrophin, that … Eteplirsen directly works on the DMD gene to promote dystrophin production. Eteplirsen was the first treatment for DMD approved by the FDA.[A244925]
Categories: Heterocyclic Compounds, 1-Ring, Compounds used in a research, industrial, or household settingSynonyms: (P-deoxy-P-(dimethylamino)](2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a→5')(C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G),5'-(P-(4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)carbonyl, )-1-piperazinyl)-N,N-dimethylphosphonamidate) RNATalimogene laherparepvec
go.drugbank.com/drugs/DB13896ApprovedInvestigationalIn general, talimogene laherparepvec has been modified so that it can infect and multiply inside melanoma cells [L2221]. … It is a genetically administered herpes simplex virus 1 (HSV-1) that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and immune-stimulating activities.
Synonyms: T Vec, T-VecCategories: Antineoplastic cell and gene therapy